Brief: Iridex Announces First Patient Enrolled In An Independent Landmark Investigator
24/06/2025 12:08
June 24 (Reuters) - IRIDEX Corp IRIX.O: IRIDEX ANNOUNCES FIRST PATIENT ENROLLED IN AN INDEPENDENT LANDMARK INVESTIGATOR-LED UK STUDY EVALUATING MICROPULSE® TECHNOLOGY AS AN ADJUNCT TO ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Source text: ID:nGNX4frs6v Further company coverage: IRIX.O ((Reuters.Briefs@thomsonreuters.com;))